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Abstract: HIV-associated neurocognitive disorders (HANDs) are one of the most important 
complications of HIV infection reported in the current literature. Although HANDs have 
been closely studied in vertically infected HIV populations or in specific subgroups such as 
drug abusers or homosexuals, they have been completely understudied in hemophilia patients 
with HIV, infected through transfusions postnatally. For this reason, it seemed interesting to 
evaluate the presence of HAND in this specific population. The aim of this work is to present a 
study protocol aimed at assessing the neuropsychological profile of HIV+ hemophilia patients 
compared with that of HIV− hemophilia patients. This is the first European study to evaluate 
the neuropsychological profile of HIV+ adult hemophiliacs prospectively.
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Background
Human immunodeficiency virus (HIV) is highly neurovirulent.1 Prior to widespread 
availability of highly active antiretroviral therapy (HAART), the prevalence of HIV-
associated cognitive impairment has been estimated to lie between 6% and 30%, and 
this impairment could progress quickly to dementia or death.2–4 The introduction of 
HAART in 1996 has resulted in the suppression of the systemic HIV-1 viral load and 
improvements in survival for patients with HIV infection.5,6 Since 2009, the term combi-
nation antiretroviral therapy (cART) has largely supplanted the more commonly known 
HAART, particularly among researchers and clinicians. It employs the use of three 
or more antiretroviral drugs, either taken individually or in fixed-dose combinations. 
Antiretroviral therapy (HAART/cART) has also been associated with an improvement in 
cognitive performance6 and a decreased incidence of HIV dementia.2,7 With treatment, 
the frequency of dementia has been attenuated, but it still remains uncertain whether the 
frequency of specific cognitive impairments in HIV infection has changed. HIV-associ-
ated neurocognitive disorders (HANDs) have not been yet eliminated, and they represent 
one of the most important complications of HIV infections.2,8,9 They are the result of 
neural damage caused by HIV replication and immune activation10 and are generally 
divided into three categories: 1) asymptomatic neurocognitive impairment, 2) mild 
neurocognitive disorder (MND), and 3) HIV-associated dementia.11 Asymptomatic 
neurocognitive impairment is detected when neuropsychological tests show HIV-
associated impairments, but routine and daily functioning is not compromised. MND 
is detected when neuropsychological tests show HIV-associated impairments and mild 
impact in routine and daily functioning. HIV-associated dementia is detected when 
neuropsychological tests show important HIV-associated impairments and a severe 
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impact on daily functioning. This impairment significantly 
limits one’s ability to function day-to-day at work, home, 
and during social activities. MND appears to be the most 
common type of HAND.11 Despite its name, even mild cog-
nitive problems can interfere with everyday functioning and 
reduce the quality of life. Estimates indicate that as many as 
50% of HIV+ individuals display some degree of cognitive 
impairment10 when impairment is derived from comparisons 
with normative performance standards.6,10
While HAND are well studied in HIV-seropositive 
(HIV+) patients infected perinatally, these disorders remain 
comparatively understudied in the HIV+ population infected 
postnatally, suggesting that research should address the 
potential for neurocognitive complications in this cohort 
of patients. Indeed, neuropsychological impairments have 
been mainly studied in HIV-seropositive (HIV+) patients 
infected postnatally during the earliest period of life of the 
child (eg, through breast milk) or in specific cohorts of adults 
such as homosexuals and drug users, but much less is known 
regarding individuals infected postnatally.12 As revealed in 
the literature, in the cohort of homosexuals and drug users, 
patients show different neuropsychological impairments, 
but these profiles are difficult to describe because they are 
often complicated by a myriad of confounding factors, 
which may be present in these patients, such as the abuse of 
substances (eg, alcohol, cocaine, and opiates),13,14 emotional 
disorders (eg, anxiety and depression),5 and different risk 
behaviors.4
Furthermore, studies on HIV+ individuals infected 
postnatally, as is the case with hemophilia patients, are 
quite rare. This group of patients is quite distinct from other 
cohorts, the children infected postnatally through transfusions 
have a different path of the infection than those who were 
infected perinatally,15–17 and they generally do not present 
certain psychosocial vulnerabilities, which are sometimes 
related to perinatal infection and which may impact as 
covariate variables. Some such factors are, for instance, the 
severe illness or death of a parent due to AIDS or a lower 
socioeconomic status. Finally, the growth of patients infected 
postnatally may be different from the growth of patients 
infected perinatally because of the differences in the rate 
of brain growth; for instance, Rubin et al18 found different 
patterns of neurobehavioral development depending on age of 
infection, and Brouwers et al19 found differences in structural 
brain abnormalities between perinatally and transfusion-
infected children.
The majority of individuals infected postnatally are 
hemophiliac patients. Due to the fact that HIV was not well 
known before 1985, many hemophilia (A/B) patients became 
silently infected through contaminated blood infusion and 
hence were at risk of developing AIDS.20 Patients with 
hemophilia are treated with injections of whole blood or other 
processed blood derivatives. Repetition of this treatment in 
the past exposed the hemophiliacs to the risk of bloodborne 
infections as HIV.21 Today, it is estimated that 60%–70% of 
people with hemophilia were infected with HIV in this way 
between 1979 and 1985.22
Hemophilia is a rare coagulation disorder in which a 
crucial clotting factor in blood is missing either partly or 
completely.23–26 Being a sex chromosome–gene-related 
bleeding disorder, it occurs primarily in the male population. 
There are two main types of hemophilia. In the more com-
mon hemophilia A (eight of ten), patients are missing or have 
low levels of clotting factor VIII, whereas in hemophilia B 
patients are missing or have low levels of clotting factor IX.27 
Most of the literature on HIV and hemophilia is derived from 
the Hemophilia Growth and Development Study (HGDS),28 
which studied the longitudinal effect of the HIV infection on 
adolescents. The main publications of HGDS, for example, 
Sirois et al,29 Whitt et al,30 and Loveland et al,17 revealed 
that most of the asymptomatic cohort of HIV+ children and 
adolescents did not vary considerably from HIV− hemophilic 
controls on several neurocognitive tests at baseline. However, 
as shown in follow-up data of HGDS patients by Tombaugh 
et al31 and by Loveland et al20 over a period of 5 years, 
the majority of these young patients showed an important 
regression in neuropsychological performance, which was 
highly correlated to declines in immune functioning status. 
This regression, however, was not clearly associated with 
HIV infection, but it was associated with socioeducational 
variables such as school absenteeism and poorer academic 
achievement. Although the HGDS represents an important 
study in pediatric population, it is a quite dated study, which 
began before the introduction of HAART. Moreover, studies 
are totally underrepresented in the adult population, with 
mixed and confusing results.32 The only two exceptions from 
literature data found no significant differences at the Mini-
Mental State Examination between patients with hemophiliac 
HIV and healthy controls;33,34 the only significant alterations 
in patients with hemophiliac HIV were found in patients suf-
fering from spontaneous brain hemorrhage (microbleeds). 
Studies on adult hemophiliacs HIV+ are also novel because 
the survival rate of such patients has increased over recent 
decades as a result of the development of new therapies.
Based on these considerations, the present study protocol 
aims to evaluate the presence of HAND in HIV+ adult 
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hemophiliacs in comparison with a control group of HIV− 
hemophiliacs by administering a full neuropsychological 
battery.
Objectives
The primary objective of this study is to compare the neurop-
sychological profiles of patients with both hemophilia and 
HIV versus the profiles of patients with hemophilia who are 
not HIV infected.
The secondary objective is to evaluate the influence of 
age and other sociodemographic data (education and working 
status) in the cognitive profile of both groups.
The influence of sociodemographic variables has been 
extensively investigated in the HIV population; however, it 
has been underestimated and not evaluated in the specific 
group of HIV+ adult hemophiliac patients.
Design
The study will apply the STROBE (STrengthening the 
Reporting of OBservational studies in Epidemiology) 
procedures for observational studies. The STROBE checklist 
criteria for cohort, case–control, and cross-sectional studies 
will be fulfilled.35 This is an observational, cross-sectional, 
prospective study to be conducted in three hemophilia 
centers: Milan, Naples, and Rome.
The study will last for 12 months, and it will involve 
45 patients with a ratio of 1:2 (15 HIV+ hemophiliacs and 
30 HIV− hemophiliacs).
The group of HIV+ hemophiliacs will have the following 
characteristics:
•	 Age $30 years
•	 Currently in cART regimens (including nucleotide 
reverse transcriptase inhibitors, nonnucleotide reverse 
transcriptase inhibitors, protease inhibitors, or integrase 
inhibitors)
•	 Diagnosis of hemophilia A or hemophilia B or von 
Willebrand disease
•	 Hemophilia diagnosis with any type of severity (severe 
hemophlia, Factor VIII [FVIII] level <1%; moderate 
hemophilia, FVIII level ranging from 1%–5%; mild 
hemophilia, FVIII level ranging from 6%–30%)
•	 Diagnosis of HIV.
The control group will have the same characteristics, 
except for the diagnosis of HIV.
The criterion of age (.30 years) was chosen based on the 
fact that patients were particularly exposed to the infection 
during the period 1979–1984 when the sources of FVIII level 
were contaminated with HIV.36
The protocol will exclude patients presenting the following 
characteristics:
•	 Presence of central neurological disorders and/or severe 
psychiatric disorders (diagnosed before/after HIV) that 
limit the execution of test assessment
•	 Presence of acute internal diseases
•	 Abuse of recreational drugs or alcohol interfering with 
everyday life in the opinion of the physician
•	 Concomitant use of antipsychotic treatment (eg, major 
tranquilizers) interfering with everyday life in the opinion 
of the physician.
Psychological assessment
Neuropsychological evaluation
Participant (HIV+ and HIV−) hemophiliacs will complete 
the Italian Brief Neuropsychological Exam,37 including the 
measurement of six major cognitive domains. In this battery, 
standardize tests are included. The battery contains the most 
important standardized test for cognitive functions and is widely 
used in the Italian context.38,39 Attention will be measured 
by Trail Making Test, which is a neuropsychological test of 
visual attention and task switching.37 Working memory will 
be detected with the digit-span memory test using the Letter-
Number Sequencing of the Wechsler Adult Intelligence Scale, 
third edition (WAIS-III),40 while phonemic memory will be 
assessed by the Verbal Fluency test.41 Abstraction, that is the 
ability of logical reasoning and generalization of concepts, 
will be measured by the Italian Test of abstraction of the Brief 
Neuropsychological Exam.37 Language will be measured with 
the short version of the Token Test, which is a valuable measure 
for assessing receptive language.42 Executive functions will be 
assessed with the Clock-Drawing Test.43 Finally, visual recogni-
tion will be detected through the Rey Tangled Lines Test.44
Evaluation of daily life activities
All patients will undergo a specific ad hoc interview for 
deterioration in daily living activities.
Study procedures
Schedule of appointments
Regular appointments are expected to be performed at the three 
Hemophilia Centers, starting with the appointment in which 
written consent of the patient to data collection is obtained.
The patient identifier will consist of two parts, by which 
the patients will be uniquely identified:
•	 Center number (two digits)
•	 Patient identification number within center (two digits).
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A participating list will be provided for each center. For 
each specific center number, each enrolled patient will be 
consecutively documented.
Statistical analysis
This is a noninterventional study, and the statistical approach 
is exploratory in nature. With the α error of 5%, and the 
power (1–β) of 80% assuming a prevalence of impairment 
of 50% in hemophilia HIV cases and of 10% in the control 
group (patients with hemophilia HIV), the sample size 
estimated to conduct the study is, at least, 15 cases and 
30 controls with a case:control ratio of 1:2. In order to avoid 
bias in the inclusion phase, a complete list of the patients will 
be collected, and they will be randomly chosen by using a 
random number generator.
Non-HIV patients will be matched with HIV patients 
by age (±5 years). The presence of HAND will be defined 
according to the cutoff normal value limits for each test, 
based on the internal control group (non-HIV hemophilic 
patients). HAND scores (for each test and as a global score) 
will be measured according to a standardized method as mild, 
moderate, and severe impairment.
Analyses will be performed using SPSS Version 21 sta-
tistical software (StataCorp LP, College Station, TX, USA). 
Alpha will be set at 0.05, two tailed. Sociodemographic 
and clinical data (age, job status, and education) will be 
descriptively analyzed by means of frequency, median, mean, 
standard deviation, range, and confidence intervals. Differ-
ences in demographic variables between HIV groups (HIV+ 
and HIV−) will be examined using analysis of variance for 
continuous variables and Pearson’s χ2 tests or Fisher’s exact 
test for categorical variables. Years of education, job status, 
and age will be included as covariates in the analyses of 
neurocognitive data. The aging effect is modeled using both 
dichotomous baseline age groups (young, ,45 years; old, 
$45 years) and continuous age.
We are also interested in analyzing effect sizes. In order 
to calculate Cohen’s d, the participants will be split into four 
groups: younger (age , 55 years) HIV−, older (age 55 years 
and above) HIV−, younger HIV+, and older HIV+. Follow-
ing these analyses, participants’ scores will be converted 
into T-scores corrected for age, education, and job status to 
compare scores to established norms.
Raw scores for the individual cognitive tests will be 
converted to population-based z scores (ie, individual score 
minus the group mean, divided by the group standard devia-
tion) using raw score distributions from the clinical sample 
(ie, older HIV-infected sample) for standardization and 
comparison purposes.
Ethical conduct and good clinical 
practice
This study will be conducted in accordance with national 
laws. Ethics committees (ECs) and national agencies will 
be informed and their approval sought. Data protection 
regulations will be strictly adhered to at all times (eg, Direc-
tive 95/46/EC). This study will be carried out completely 
independent of any medicinal treatment recommendations. 
Patients will be assessed and treated according to the indi-
vidual decision of the attending physician. The study will 
not provide any recommendations with regard to diagnostic 
procedures or dosages, time of intake, or the strength of any 
medication. All decisions are to be made by the physician 
in the best interest of the patient’s care.
Ethics committee and authority
Before the study begins, the noninterventional plan, written 
data protection form(s), and/or other appropriate documents 
will be submitted to the EC, in accordance with local legal 
requirements. The patients will be provided with appropriate 
forms for obtaining written consent for data collection. In 
the case of minors, a written consent for the collection of 
data from the respective patient must also be obtained from 
the patient’s parents or a legally authorized representative, as 
applicable, after adequate explanation of the purposes of this 
observational study and the objectives of data collection.
Conclusion
The last 2 decades have borne witness to dramatic improve-
ments in the availability and quality of treatment for persons 
with HIV. Accordingly, a considerable number of these 
patients now live longer. In the context of hemophilia, the 
introduction of virus-inactivated plasma-derived coagulation 
factors and recombinant products has revolutionized the care 
of people with hemophilia, improving their health-related 
quality of life and life expectancy. However, living with two 
severe conditions such as HIV and hemophilia is challeng-
ing. As with any medical condition, it is very important to 
evaluate the psychological and cognitive processes related 
to multiple diseases and multiple treatments.45–49 This study 
is unique in the field of hemophilia, and it will offer an 
in-depth evaluation of the neuropsychological profile and 
a psychoemotional assessment of this particular cohort of 
patients with HIV.
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